The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Investigators sought to identify perceived barriers to adopting healthy lifestyle behaviors in cancer patients and survivors.

Regulating artificial intelligence, especially its use by health insurers, is becoming a politically divisive topic, and it’s scrambling traditional partisan lines.

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1 ...

In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.

On the same day the lawsuit was filed, the administration also announced plans to cut another $183 million in unused public health funds. That round of cuts includes block grants from the U.S. Centers ...

Study researchers surveyed community-based physicians in order to understand what drives treatment decision-making in mCRC in the third-line setting.

The NDA is supported by data from part A of the phase 2 PROSPECT trial, which evaluated tirabrutinib in 48 adult patients with R/R PCNSL.

In this analysis, researchers aimed to determine whether intermediate dose escalation is beneficial in resectable, stage III NSCLC patients who receive definitive concurrent chemoradiation followed by ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.